Atlas Trials

Study of Pembrolizumab Following TACE in Primary Liver Carcinoma

Clinical trial NCT03397654 · COMPLETED

Trial details

NCT number
NCT03397654
Sponsor
Imperial College London
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Primary Liver Carcinoma
Start date
2018-01-28
Primary completion
2023-02-01
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.